<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04214015</url>
  </required_header>
  <id_info>
    <org_study_id>ProgenaBiome-035</org_study_id>
    <nct_id>NCT04214015</nct_id>
  </id_info>
  <brief_title>A Pilot Study to Explore the Role of Gut Flora in Metastatic Mesothelioma</brief_title>
  <official_title>A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Metastatic Mesothelioma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ProgenaBiome</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ProgenaBiome</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study seeks to correlate microbiome sequencing data with information provided by
      patients and their medical records.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The goal of this Research Study is to better understand how the genetic information in
      subject's microbiome correlates to Metastatic Mesothelioma
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 2, 2020</start_date>
  <completion_date type="Anticipated">July 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Correlation of Microbiome to Disease via Relative Abundance Found in Microbiome Sequencing</measure>
    <time_frame>Three years</time_frame>
    <description>Relative abundance of bacterial classes within taxonomic phyla and, more broadly, within their domain will be analyzed by sequencing the gut microbiome. These data will then be categorized with metastatic mesothelioma</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Mesothelioma</condition>
  <condition>Mesothelioma Malignant</condition>
  <condition>Mesothelioma; Lung</condition>
  <condition>Mesotheliomas Pleural</condition>
  <condition>Mesothelioma Peritoneum</condition>
  <condition>Mesothelioma; Liver</condition>
  <condition>Mesothelioma; Omentum</condition>
  <arm_group>
    <arm_group_label>Patients with metastatic mesothelioma</arm_group_label>
    <description>Patients who have been diagnosed with metastatic mesothelioma</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention</intervention_name>
    <description>There is no intervention for this study</description>
    <arm_group_label>Patients with metastatic mesothelioma</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Stool samples
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with metastatic mesothelioma
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed informed consent, demonstrating that the patient understands the procedures
             required for the study and the purpose of the study

             a. May be signed by parent or legal guardian in the case of minor or adult unable to
             provide consent

          2. Male or female of all ages. (interest is given to children who present with autism or
             Crohn's and whose parents wish to analyze their children's gut flora. Also of interest
             analysis of development of the child's microbiome. In the case of autism, the younger
             the child, the better to correct the neurological problems if an association is found
             between autism and the microbiome)

          3. Diagnosis of metastatic mesothelioma through biopsy and/or advanced imaging

        Exclusion Criteria:

          1. Refusal to sign informed consent form

          2. History of bariatric surgery, total colectomy with ileorectal anastomosis or
             proctocolectomy.

          3. Postoperative stoma, ostomy, or ileoanal pouch

          4. Participation in any experimental drug protocol within the past 12 weeks

          5. Treatment with total parenteral nutrition
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sabine Hazan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>ProgenaBiome</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sabine Hazan, MD</last_name>
    <phone>8053390549</phone>
    <email>sabinehazan@aim.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jordan Daniels, MS</last_name>
    <phone>8053390549</phone>
    <email>msjordandaniels@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>ProgenaBiome</name>
      <address>
        <city>Ventura</city>
        <state>California</state>
        <zip>93003</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sabine Hazan, MD</last_name>
      <phone>805-339-0549</phone>
      <email>sabinehazan@aim.com</email>
    </contact>
    <contact_backup>
      <last_name>Jordan Daniels, MS</last_name>
      <phone>805-339-0549</phone>
      <email>msjordandaniels@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Sabine Hazan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>December 27, 2019</study_first_submitted>
  <study_first_submitted_qc>December 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 30, 2019</study_first_posted>
  <last_update_submitted>March 4, 2020</last_update_submitted>
  <last_update_submitted_qc>March 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mesothelioma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>There is no plan to share IPD</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

